Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement (Q37067902)

18 August 2017

Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement (English)

1 reference

18 August 2017

Gram-negative bacteria

0 references

Keith Miller

5

0 references

Ian Chopra

1

object named as

Ian Chopra

1 reference

18 August 2017

4

Alex O'Neill

1 reference

18 August 2017

6

Mark Wilcox

1 reference

18 August 2017

Christopher J. Schofield

2

object named as

Christopher Schofield

1 reference

18 August 2017

Martin Everett

3

1 reference

18 August 2017

Jean-Marie Frère

7

1 reference

18 August 2017

Mike Dawson

8

1 reference

18 August 2017

Lloyd Czaplewski

9

1 reference

18 August 2017

Uros Urleb

10

1 reference

18 August 2017

Patrice Courvalin

11

1 reference

18 August 2017

1 February 2008

1 reference

Lancet Infectious Diseases

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

133-139

1 reference

18 August 2017

2

1 reference

Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Mechanisms of action of newer antibiotics for Gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

1 reference

7 January 2021

The glycylcyclines: a comparative review with the tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Quinupristin-dalfopristin and linezolid: evidence and opinion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Old polymyxins are back: is resistance close?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Anti-infective research and development--problems, challenges, and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

The future challenges facing the development of new antimicrobial drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Lack of development of new antimicrobial drugs: a potential serious threat to public health.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

The need for new antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antimicrobial resistance: paradox, actions and economics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antibacterial drug discovery: is it all downhill from here?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antibacterial drug discovery in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antimicrobial drug development--the past, the present, and the future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Resistance to antibiotics: are we in the post-antibiotic era?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Overview of nosocomial infections caused by gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Surveillance of antimicrobial resistance of invasive pathogens: the Estonian experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Resistance in gram-negative bacteria: Enterobacteriaceae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Serious Infections in the Intensive Care Unit: Pseudomonas aeruginosa and Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3'')-Ii/AAC(6')-IId from Serratia marcescens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

The worldwide emergence of plasmid-mediated quinolone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Why is big Pharma getting out of antibacterial drug discovery?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antimicrobials: new solutions badly needed

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antimicrobial drug resistance, regulation, and research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Antibacterial discovery and development--the failure of success?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Where have all the antibiotic patents gone?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Sampling the antibiotic resistome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

The biological cost of mutational antibiotic resistance: any practical conclusions?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

(Genome) size matters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Comparative genomics of multidrug resistance in Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Exploiting current understanding of antibiotic action for discovery of new drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Can biotech deliver new antibiotics?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Drug discovery in jeopardy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Biomedical research. A cure for medicine's ailments?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Phosphonate inhibitors of antigen 85C, a crucial enzyme involved in the biosynthesis of the Mycobacterium tuberculosis cell wall

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme MurD.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

New lipophilic phthalimido- and 3-phenoxybenzyl sulfonates: inhibition of antigen 85C mycolyltransferase activity and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

Design, synthesis and structure-activity relationships of new phosphinate inhibitors of MurD.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970018-5

7 January 2021

10.1016/S1473-3099(08)70018-5

Identifiers

DOI

1 reference

18 August 2017

1 reference